📰 Immunic News
Page 5 - Immunic News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Immunic. Real-time updates on events, politics, business and more.
May 11, 2023
– Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease Provide Proof-of-Concept for a New Therapeutic Approach to Treat Gastrointestinal...
May 11, 2023
Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update Positive Results From Phase 1b Clinical... | May 11, 2023
May 10, 2023
Immunic (NASDAQ:IMUX – Get Rating) is set to release its earnings data before the market opens on Thursday, May 11th. Analysts expect Immunic to post earnings of ($0.54) per share for the quarter. Immunic (NASDAQ:IMUX – Get Rating) last issued its earnings results on Thursday, February 23rd. The company reported ($1.63) earnings per share (EPS) […]
May 9, 2023
– Webcast to be Held at 8:00 am ET on May 11, 2023 – NEW YORK, May 9, 2023 /PRNewswire/ -- Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally... | May 9, 2023
May 6, 2023
Issuer: Immunic, Inc. / Key word(s): Study/Conference Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action 06.05.2023
May 6, 2023
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
May 4, 2023
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
May 4, 2023
Issuer: Immunic, Inc. / Key word(s): Study results Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic
May 4, 2023
<iframe src=https://www.youtube.com/embed/wm5ic6gVQso></iframe>Immunic Inc CEO Dr. Daniel Vitt speaks to Thomas Warner from Proactive after releasing new clinical trial data for the... | May 4, 2023
April 27, 2023
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...